News
-
-
PRESS RELEASE
NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT
NanoViricides, Inc. announces Annual Shareholders Meeting to discuss progress on NV-387, a potential treatment for MPox Clade I. Clinical trials underway -
-
PRESS RELEASE
NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd
NanoViricides, Inc. to present groundbreaking antiviral drug NV-387 at Spartan Capital Investor Conference. CEO Diwan to update on drug pipeline & Platform Technologies for licensing -
-
PRESS RELEASE
Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive
NanoViricides, Inc. announced progress in antiviral research with their drug NV-387 showing potent activity against Measles virus. Clinical trials have shown safety and effectiveness, positioning for emergency use -
-
-
-
PRESS RELEASE
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
NanoViricides, Inc. announces promising results for drug NV-387 against Measles virus, showing dual benefits in cell culture and animal models. NV-387 also demonstrates safety and unique mechanism of action
